Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Document Type
Journal Article
Publication Date
3-21-2015
Journal
Lancet
Volume
385
Issue
9973
Inclusive Pages
1107-13
DOI
10.1016/S0140-6736(14)61228-9
Keywords
Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; RNA, Viral; Ribavirin; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load
APA Citation
Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E., Barrett, L., Townsend, K., & + several additional authors (2015). Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.. Lancet, 385 (9973). http://dx.doi.org/10.1016/S0140-6736(14)61228-9
Peer Reviewed
1
